Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04537013 · ClinicalTrials.gov registry record · NA
Clinical Study of Chondro-Gide® for Large Chondral Lesions in the Knee
A NA study, sponsored by Geistlich Pharma.
- Terminated
- Registry status
- NA
- Development phase
- 82
- Enrollment target
NCT04537013: Clinical Trial NA study, sponsored by Geistlich Pharma.
NCT04537013 is a NA study that was terminated before completion, run by Geistlich Pharma. The registered enrollment target is 82 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (94% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04537013, a NA study, was terminated before completion, sponsored by Geistlich Pharma.
- TERMINATED
- Registry status
- NA
- Development phase
- 82 participants
- Enrollment target
Study Summary
Multi-center, prospective, concurrently controlled, non-randomized, double-blind (patient and assessor). Treatment of large chondral lesions in the knee with microfracture plus the Chondro-Gide® ACC is non-inferior to treatment of small chondral lesions treated with microfracture alone.
Primary Outcome
The CCS is defined as a patient meeting all of the three following criteria: 1. Improvement in the Pain sub-scale of the Knee Injury and Osteoarthritis Outcomes Score (KOOS) between baseline to 24 months follow-up 2. Improvement in function, defined as an improvement in the International Knee Documentation Committee (IKDC) score between baseline to 24 months follow-up 3. Freedom from device- or procedure-related serious adverse events (SAEs) or secondary surgical intervention related to the dev
Interventions
- PROCEDURE Microfracture
- DEVICE Microfracture plus placement of Chondro-Gide® ACC
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 82 participants |
| Start Date | 2020-08-26 |
| Est. Completion | 2025-09-29 |
| Phase | NA |
Why NCT04537013 stopped before completion
NCT04537013 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 82 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (94% lower).
The record links to 0 conditions, and to 2 interventions - of which Microfracture is the first listed.
NCT04537013 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04537013 about?
NCT04537013 is a clinical study titled "Clinical Study of Chondro-Gide® for Large Chondral Lesions in the Knee". Multi-center, prospective, concurrently controlled, non-randomized, double-blind (patient and assessor). Treatment of large chondral lesions in the knee with microfracture plus the Chondro-Gide® ACC is non-inferior to treatment of small chondral lesions treated with microfracture alone.
What is the current status of trial NCT04537013?
This trial is currently terminated. It is a NA study. The enrollment target is 82 participants. The study started on 2020-08-26. Estimated completion is 2025-09-29.
What interventions are being tested in trial NCT04537013?
The interventions under investigation include: Microfracture (PROCEDURE), Microfracture plus placement of Chondro-Gide® ACC (DEVICE).
Who is sponsoring clinical trial NCT04537013?
This trial is sponsored by Geistlich Pharma, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04537013's enrollment target sits among peer trials
82 990th of 2000 higher than 1,009 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03319901 · 82 participants · Phase 1
Venetoclax and Chemotherapy as Frontline Therapy in Older Patients and Patients With Relapsed/Refractory ALL
- NCT03493425 · 82 participants · Phase 2
Chemotherapy Before Surgery and Radiation Therapy or Surgery and Radiation Therapy Alone in Treating Patients With Nasal and Paranasal Sinus Cancer That Can Be Removed by Surgery
- NCT04105270 · 82 participants · Phase 2
RMT in Combination With Durvalumab + Chemo in Untreated Adenocarcinoma NSCLC. A Randomized Double Blind Phase II Trial
- NCT04428658 · 82 participants · NA
Randomized Trial of Supplemental Synchronous and Asynchronous Telehealth to Improve Glycemic Control for Pediatric Patients With Type 1 Diabetes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI